IL-7 Receptor Polymorphisms and Immune Recovery With HAART

The Alfred106 enrolled

Overview

The aim is to investigate the hypothesis that IL7-receptor polymorphisms contribute to the differential immune recovery of CD4 + T cells following HAART

AIM: To examine the association between the four haplotypes of IL-7Rα gene and a cohort of HIV infected patients who have commenced HAART with varying CD4+ T lymphocyte responses. METHODS: IL-7Rα gene SNPs and haplotypes will be measured by constructing DNA pools, and PCR amplification and DNA sequencing. IL-7Rα expression will be examined using constitutive expression of IL-7Rα, IL-7Rα gene expression, and inducible expression of IL7Rα.

Study Type

OBSERVATIONAL

Enrollment

106

Conditions

HIV Infections

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men or women at least 18 years of age * First antiretroviral regimen composed of HAART as defined by at least three antiretrovirals * Controlled viremia for a period of at least 12 months following commencement of HAART. Controlled viremia is defined as HIV viral load of ≤ 500 copies/mL on bDNA testing (versions 2 and 3) and \<400 copies/ml measured by RT-PCR assay by 6 months treatment. * CD4 cell count \<500 at commencement of HAART * Measurement of CD4+ cell count on at least 3 time points, in the 12 months post commencement of HAART. Exclusion Criteria: * Exclude patients treated for HIV seroconversion illness * Exclude patients on immunomodulatory therapy such as IL-2, hydroxyurea or prednisolone or who have received an HIV therapeutic vaccine

Locations (1)

The Alfred Hospital, Commercial Road

Melbourne, Victoria, Australia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.